Laboratory Corporation of America Holdings(LH) Stock Research - Grey Stern Research
Loading...

Laboratory Corporation of America Holdings (LH) Stock Analysis

$238.56 (-0.09%)

LH Financial Performance


Use the table below to view Laboratory Corporation of America Holdings's financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q2 - 2024

Metric Value Ranking among Peers
Price $238.56 -
52 Week Low $191.97 -
52 Week High $247.99 -
Market Cap $20.0 Billion 3/6
Gross Margin 28% 5/6
Profit Margin 5% 5/6
EBITDA margin 13% 2/6
Q2 - 2024 Revenue $3.3 Billion 3/6
Q2 - 2024 Earnings $169.3 Million 5/6
Q2 - 2024 Free Cash Flow $161.5 Million 4/6
Trailing 4 Quarters Revenue $12.7 Billion 3/6
Trailing 4 Quarters Earnings $435.5 Million 6/6
Quarterly Earnings Growth -10% 5/6
Annual Earnings Growth -47% 5/6
Quarterly Revenue Growth 8% 3/6
Annual Revenue Growth -12% 5/6
Cash On Hand $1.5 Billion 3/6
Short Term Debt $1.4 Billion 1/6
Long Term Debt $5.4 Billion 3/6

Laboratory Corporation of America Holdings Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Laboratory Corporation of America Holdings's metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 45.82 1/6
PS 1.57 4/6
PB 2.44 4/6
PC 13.15 4/6
Liabilities to Equity 1.28 4/6
ROA 0.02 6/6
ROE 0.05 6/6
Current Ratio 1.79 3/6
Quick Ratio 0.15 3/6
Long Term Debt to Equity 0.66 4/6
Debt to Equity 0.83 2/6
Burn Rate 3.84 2/6
Cash to Cap 0.08 3/6
CCR 0.95 3/6
EV to EBITDA 59.62 3/6
EV to Revenue 1.98 4/6

Company Details

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, and parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. It provides online and mobile applications to enable patients to check test results; and online applications for managed care organizations. It offers end-to-end drug development, medical device, and diagnostic development solutions from early-stage research to clinical development and commercial market access. It serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, and independent clinical laboratories. The company was founded in 1971 and is headquartered in Burlington, North Carolina.

CEO: Mr. Adam Schechter

Website: https://www.labcorp.com

Address: 358 S MAIN ST Burlington, NORTH CAROLINA

Exchange: New York Stock Exchange

Industry: Diagnostics & Research

Laboratory Corporation of America Holdings Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Laboratory Corporation of America Holdings. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Hologic, Inc. HOLX $15.8 Billion
Universal Health Services, Inc. UHS $10.9 Billion
Quest Diagnostics Incorporated DGX $16.9 Billion
Humana Inc. HUM $34.0 Billion
Waters Corporation WAT $24.0 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
LH Income Statements
Quarter Year Revenue Earnings
Q2 2024 $ 3.3 Billion $169.3 Million
Q1 2024 $ 3.2 Billion $205.3 Million
Q4 2023 $ 3.2 Billion $228.0 Million
Q3 2023 $ 3.0 Billion -$167.1 Million
Q2 2023 $ 3.0 Billion $188.9 Million
Q1 2023 $ 3.8 Billion $212.9 Million
Q4 2022 $ 3.7 Billion $76.1 Million
Q3 2022 $ 3.6 Billion $352.8 Million

View All

LH Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q2 2024 $1.5 Billion $18.6 Billion $6.8 Billion $8.2 Billion
Q1 2024 $265.1 Million $16.7 Billion $6.0 Billion $8.0 Billion
Q4 2023 $99.3 Million $16.5 Billion $6.0 Billion $8.0 Billion
Q3 2023 $536.8 Million $16.7 Billion $6.0 Billion $7.9 Billion
Q2 2023 $1.9 Billion $17.7 Billion $6.2 Billion $8.8 Billion
Q1 2023 $393.9 Million $20.2 Billion $6.3 Billion $10.3 Billion
Q4 2022 $430.0 Million $20.2 Billion $6.3 Billion $10.1 Billion
Q3 2022 $409.9 Million $19.8 Billion $6.3 Billion $10.1 Billion

View All

LH Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q2 2024 $161.5 Million -$115.8 Million $1.3 Billion
Q1 2024 $432.9 Million -$128.2 Million $165.8 Million
Q4 2023 -$163.6 Million -$133.8 Million -$437.5 Million
Q3 2023 $414.2 Million -$165.4 Million -$191.1 Million
Q2 2023 $248.8 Million -$102.6 Million $1.5 Billion
Q1 2023 $27.3 Million -$93.9 Million -$36.1 Million
Q4 2022 $535.7 Million -$117.9 Million $20.1 Million
Q3 2022 $270.3 Million -$103.5 Million -$658.9 Million

View All